re: AUPH - Aurinia Pharmaceuticals

Who created the current standard of care for Lupus Nephritis?

Richard Glickman did it back in 2009. He's currently the CEO of Aurinia Pharmaceuticals (AUPH).

He's merely improving on his own drug, and he and others who are patient are going to receive one hell of a paycheck.

This is a two billion dollar market, and it is virtually unmet (hence Voclosporin--AUPH's drug).

DES/Dry Eye Syndrome is also a >billion dollar market under the current standard of care, Restasis...enter VOS, a new indication for Voclosporin.

VOS is an aqueous, preservative free nanomicellar solution containing 0.2% voclosporin intended for use in the treatment of DES. Studies have been completed in rabbit and dog models, and a single Phase I has also been completed in healthy volunteers and patients with DES. VOS has IP protection until 2031. In April 2017, Aurinia announced an agreement granting Merck Animal Health (MAH) worldwide rights to develop and commercialize (VOS) for the treatment of DES in dogs. (but it has kept the rights for treatment in humans)...

Data for VOS and DES comes out second half of next year. Upon success, I can Glickman selling off VOS for 600 to 800 million in order to focus his company on renal (kidney) diseases. He's stated that AUPH is a renal solutions company. Selling VOS would automatically double the value of the company.

I really don't understand why this thing has flirted with four dollars today. Are people so dumb to sell a non revenue producing pharma because it showed a quarterly loss of 14 cents per share?? We've got 182 million dollars to see Phase III through!
I honestly think that a fair price at the moment is around $8 (worth around 600 million dollars) Hell, all the price targets have it above $10...

I'd say the five year outlook here is somewhere near 4 billion in market cap.